| pubmed-article:21159616 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21159616 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21159616 | lifeskim:mentions | umls-concept:C0877373 | lld:lifeskim |
| pubmed-article:21159616 | lifeskim:mentions | umls-concept:C0026046 | lld:lifeskim |
| pubmed-article:21159616 | lifeskim:mentions | umls-concept:C0450442 | lld:lifeskim |
| pubmed-article:21159616 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:21159616 | lifeskim:mentions | umls-concept:C1832001 | lld:lifeskim |
| pubmed-article:21159616 | lifeskim:mentions | umls-concept:C1881500 | lld:lifeskim |
| pubmed-article:21159616 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:21159616 | pubmed:dateCreated | 2010-12-16 | lld:pubmed |
| pubmed-article:21159616 | pubmed:abstractText | MPC-6827 (Azixa) is a small-molecule microtubule-destabilizing agent that binds to the same (or nearby) sites on ?-tubulin as colchicine. This phase I study was designed to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of MPC-6827 in patients with solid tumors. Patients with advanced/metastatic cancer were treated with once-weekly, 1- to 2-hour intravenous administration of MPC-6827 for 3 consecutive weeks every 28 days (1 cycle). Dose escalation began with 0.3, 0.6, 1, and 1.5 mg/m(2), with subsequent increments of 0.6 mg/m(2) until the MTD was determined. A 3 + 3 design was used. Pharmacokinetics of MPC-6827 and its metabolite MPI-0440627 were evaluated. Forty-eight patients received therapy; 79 cycles were completed (median, 1; range, 1-10). The most common adverse events were nausea, fatigue, flushing, and hyperglycemia. The DLT was nonfatal grade 3 myocardial infarction at 3.9 mg/m(2) (1/6 patients) and at 4.5 mg/m(2) (1/7 patients). The MTD was determined to be 3.3 mg/m(2) (0/13 patients had a DLT). Five (10.4%) of the 48 patients achieved stable disease (Response Evaluation Criteria in Solid Tumors) for 4 months or greater. MPC-6827 has a high volume of distribution and clearance. Half-life ranged from 3.8 to 7.5 hours. In conclusion, MPC-6827 administered intravenously over 2 hours at a dose of 3.3 mg/m(2) once weekly for 3 weeks every 28 days was safe in patients with heavily pretreated cancer. Clinical trials with MPC-6827 and chemotherapy are ongoing. | lld:pubmed |
| pubmed-article:21159616 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21159616 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21159616 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21159616 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21159616 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21159616 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21159616 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21159616 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21159616 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21159616 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:21159616 | pubmed:issn | 1538-8514 | lld:pubmed |
| pubmed-article:21159616 | pubmed:author | pubmed-author:KurzrockRazel... | lld:pubmed |
| pubmed-article:21159616 | pubmed:author | pubmed-author:AkerleyWallac... | lld:pubmed |
| pubmed-article:21159616 | pubmed:author | pubmed-author:WarrenTerriT | lld:pubmed |
| pubmed-article:21159616 | pubmed:author | pubmed-author:TsimberidouAp... | lld:pubmed |
| pubmed-article:21159616 | pubmed:author | pubmed-author:EvansBrent... | lld:pubmed |
| pubmed-article:21159616 | pubmed:author | pubmed-author:HongDavid SDS | lld:pubmed |
| pubmed-article:21159616 | pubmed:author | pubmed-author:SchabelMatthi... | lld:pubmed |
| pubmed-article:21159616 | pubmed:author | pubmed-author:SwabbEdward... | lld:pubmed |
| pubmed-article:21159616 | pubmed:author | pubmed-author:MatherGary... | lld:pubmed |
| pubmed-article:21159616 | pubmed:author | pubmed-author:ChhabraAnilA | lld:pubmed |
| pubmed-article:21159616 | pubmed:author | pubmed-author:UeharaCynthia... | lld:pubmed |
| pubmed-article:21159616 | pubmed:author | pubmed-author:WoodlandDeane... | lld:pubmed |
| pubmed-article:21159616 | pubmed:copyrightInfo | ©2010 AACR. | lld:pubmed |
| pubmed-article:21159616 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21159616 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:21159616 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21159616 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21159616 | pubmed:pagination | 3410-9 | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:meshHeading | pubmed-meshheading:21159616... | lld:pubmed |
| pubmed-article:21159616 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:21159616 | pubmed:articleTitle | Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. | lld:pubmed |
| pubmed-article:21159616 | pubmed:affiliation | Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. atsimber@mdanderson.org | lld:pubmed |
| pubmed-article:21159616 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21159616 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21159616 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:21159616 | lld:pubmed |
